Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANNA HALPERN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1952531790
CMS profile
704057
Location
SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$3,300.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,300.00 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Agios Pharmaceuticals, Inc. $3,300.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANNA HALPERN

NPI 1952531790 · CMS profile ID 704057

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952531790?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANNA HALPERN, NPI 1952531790, CMS profile ID 704057. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952531790?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ANNA HALPERN, NPI 1952531790, CMS profile ID 704057. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952531790?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ANNA HALPERN, NPI 1952531790, CMS profile ID 704057, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1952531790?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $3,300.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Agios Pharmaceuticals, Inc. $3,300.0007/29/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751971001 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $3,300.00 1
PY2021 $1,660.00 2
PY2022 $585.67 2
PY2023 $1,223.26 3
PY2024 $277.32 5
PY2025 $6,539.93 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $827,949.32 641
PY2024 Principal investigator $566,406.00 261
PY2023 Principal investigator $102,938.19 71
PY2022 Principal investigator $588,631.39 40
PY2021 Principal investigator $751,174.50 8
PY2020 Principal investigator $363,188.60 3
PY2019 Principal investigator $200.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

261 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Sumitomo Pharma America, Inc. $1,200.00 12/31/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-Risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445529
Principal investigator 1 Incyte Corporation $10.20 12/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675205
Principal investigator 1 Incyte Corporation $20.40 12/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675207
Principal investigator 1 Incyte Corporation $38.80 12/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675209
Principal investigator 1 Incyte Corporation $44.00 12/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675211
Principal investigator 1 Incyte Corporation $38.80 12/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675213
Principal investigator 1 Incyte Corporation $0.50 12/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675231
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441878
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441882
Principal investigator 1 Sumitomo Pharma America, Inc. $16.06 12/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442503
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442954
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442956
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443867
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443869
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148444319
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148444321
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148444323
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148444325
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148444327
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148444329
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445257
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445259
Principal investigator 1 Incyte Corporation $12,203.90 11/27/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675267
Principal investigator 1 PharmaEssentia USA Corporation $4,010.00 11/22/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2bnjft(P1101) in Adult Patients with Essential Thrombocythemia No dispute reported 06/30/2026 1137325257
Principal investigator 1 PharmaEssentia USA Corporation $11,513.00 11/22/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2bnjft(P1101) in Adult Patients with Essential Thrombocythemia No dispute reported 06/30/2026 1137325261
Principal investigator 1 Incyte Corporation $108.00 11/21/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675217
Principal investigator 1 Sumitomo Pharma America, Inc. $1,050.00 11/07/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-Risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148446085
Principal investigator 1 PharmaEssentia USA Corporation $9,215.00 10/22/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2bnjft(P1101) in Adult Patients with Essential Thrombocythemia No dispute reported 06/30/2026 1137325245
Principal investigator 1 PharmaEssentia USA Corporation $1,619.25 10/22/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2bnjft(P1101) in Adult Patients with Essential Thrombocythemia No dispute reported 06/30/2026 1137325249
Principal investigator 1 Incyte Corporation $4,956.30 10/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675219
Principal investigator 1 Incyte Corporation $5,273.10 10/02/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675265
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441814
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441818
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441822
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441826
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441830
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441834
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441838
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441842
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441846
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441850
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441854
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441858
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441862
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441866
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441870
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441874
Principal investigator 1 Sumitomo Pharma America, Inc. $90.96 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442499
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442930
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442932
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442934
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442936
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442938
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442940
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442942
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442944
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442946
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442948
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442950
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442952
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443827
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443829
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443831
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443833
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443835
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443837
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443839
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443841
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443843
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443845
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443847
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443849
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443851
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443853
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443855
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443857
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443859
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443861
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443863
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443865
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445209
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445211
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445213
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445215
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445217
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445219
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445221
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445223
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445225
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445227
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445229
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445231
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445233
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445235
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445237
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445239
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445241
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445243
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445245
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445247
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445249
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445251
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445253
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445255
Principal investigator 1 PharmaEssentia USA Corporation $425.00 09/26/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2bnjft(P1101) in Adult Patients with Essential Thrombocythemia No dispute reported 06/30/2026 1137325253
Principal investigator 1 Sumitomo Pharma America, Inc. $5,545.00 09/26/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-Risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148446083
Principal investigator 1 PharmaEssentia USA Corporation $86,668.70 09/25/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2bnjft(P1101) in Adult Patients with Essential Thrombocythemia No dispute reported 06/30/2026 1137325241
Principal investigator 1 Incyte Corporation $20.42 09/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675193
Principal investigator 1 Incyte Corporation $32.50 09/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675197
Principal investigator 1 Incyte Corporation $77.60 09/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675199
Principal investigator 1 Incyte Corporation $20.42 09/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675201
Principal investigator 1 Incyte Corporation $77.60 09/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675203
Principal investigator 1 Incyte Corporation $20.42 09/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675215
Principal investigator 1 Incyte Corporation $81.68 09/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675221
Principal investigator 1 Incyte Corporation $20.42 09/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675245
Principal investigator 1 Incyte Corporation $20.42 09/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675247
Principal investigator 1 PharmaEssentia USA Corporation $1,408.00 09/06/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2bnjft(P1101) in Adult Patients with Essential Thrombocythemia No dispute reported 06/30/2026 1137325237
Principal investigator 1 Incyte Corporation $4,378.00 08/29/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675169
Principal investigator 1 Incyte Corporation $5,562.00 08/15/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675171
Principal investigator 1 Incyte Corporation $97.00 08/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675161
Principal investigator 1 Incyte Corporation $6,850.00 08/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675163
Principal investigator 1 Incyte Corporation $4,080.00 08/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675165
Principal investigator 1 Incyte Corporation $288.00 08/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675167
Principal investigator 1 Incyte Corporation $8.16 08/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675111
Principal investigator 1 Incyte Corporation $8,343.00 08/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675173
Principal investigator 1 Incyte Corporation $0.60 08/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675179
Principal investigator 1 Incyte Corporation $2.00 08/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675183
Principal investigator 1 Incyte Corporation $6.76 08/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675185
Principal investigator 1 Incyte Corporation $1.75 08/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675187
Principal investigator 1 Incyte Corporation $275.40 08/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675189
Principal investigator 1 Incyte Corporation $66.66 08/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675191
Principal investigator 1 Incyte Corporation $164.48 08/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675195
Principal investigator 1 Incyte Corporation $20.26 08/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675225
Principal investigator 1 Incyte Corporation $50.19 08/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675243
Principal investigator 1 Incyte Corporation $176.16 08/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675255
Principal investigator 1 Incyte Corporation $7.38 08/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675259
Principal investigator 1 Incyte Corporation $7.16 08/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675261
Principal investigator 1 Incyte Corporation $7.40 08/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675263
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441774
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441778
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441782
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441786
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441790
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441794
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441798
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441802
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441806
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441810
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442922
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442924
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442926
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442928
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443787
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443789
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443791
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443793
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443795
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443797
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443799
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443801
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443803
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443805
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443807
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443809
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443811
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443813
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443815
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443817
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443819
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443821
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443823
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443825
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148444311
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148444313
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148444315
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148444317
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445173
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445175
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445177
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445179
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445181
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445183
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445185
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445187
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445189
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445191
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445193
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445195
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445197
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445199
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445201
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445203
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445205
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 08/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445207
Principal investigator 1 PharmaEssentia USA Corporation $2,400.00 07/30/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2bnjft(P1101) in Adult Patients with Essential Thrombocythemia No dispute reported 06/30/2026 1137325229
Principal investigator 1 PharmaEssentia USA Corporation $8,585.20 07/30/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2bnjft(P1101) in Adult Patients with Essential Thrombocythemia No dispute reported 06/30/2026 1137325233
Principal investigator 1 Incyte Corporation $6,577.20 07/26/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675159
Principal investigator 1 PharmaEssentia USA Corporation $18,711.00 07/16/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2bnjft(P1101) in Adult Patients with Essential Thrombocythemia No dispute reported 06/30/2026 1137325225
Principal investigator 1 Incyte Corporation $30.63 07/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675175
Principal investigator 1 Incyte Corporation $0.50 07/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675177
Principal investigator 1 Incyte Corporation $33.80 07/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675181
Principal investigator 1 Incyte Corporation $61.68 07/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675233
Principal investigator 1 Incyte Corporation $22.02 07/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675235
Principal investigator 1 Incyte Corporation $51.05 07/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675257
Principal investigator 1 Incyte Corporation $288.00 06/14/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675141
Principal investigator 1 PharmaEssentia USA Corporation $54,090.00 06/14/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2bnjft(P1101) in Adult Patients with Essential Thrombocythemia No dispute reported 06/30/2026 1137325217
Principal investigator 1 PharmaEssentia USA Corporation $9,405.69 06/14/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2bnjft(P1101) in Adult Patients with Essential Thrombocythemia No dispute reported 06/30/2026 1137325221
Principal investigator 1 Incyte Corporation $33.80 06/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675145
Principal investigator 1 Incyte Corporation $20.42 06/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675147
Principal investigator 1 Incyte Corporation $44.04 06/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675149
Principal investigator 1 Incyte Corporation $41.12 06/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675151
Principal investigator 1 Incyte Corporation $0.50 06/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675153
Principal investigator 1 Incyte Corporation $33.80 06/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675155
Principal investigator 1 Incyte Corporation $10.21 06/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675241
Principal investigator 1 Incyte Corporation $20.42 06/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675249
Principal investigator 1 Incyte Corporation $20.42 06/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675251
Principal investigator 1 Sumitomo Pharma America, Inc. $4,683.00 05/30/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-Risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148446081
Principal investigator 1 Incyte Corporation $256.54 05/23/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675135
Principal investigator 1 Incyte Corporation $4,628.70 05/10/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675137
Principal investigator 1 Incyte Corporation $9,458.00 05/09/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675139
Principal investigator 1 Incyte Corporation $6.76 05/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675143
Principal investigator 1 Incyte Corporation $70.32 05/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675157
Principal investigator 1 Incyte Corporation $70.32 05/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675237
Principal investigator 1 Incyte Corporation $110,416.00 05/02/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675239
Principal investigator 1 Incyte Corporation $327.66 04/25/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675133
Principal investigator 1 Incyte Corporation $24,474.00 04/11/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675129
Principal investigator 1 Incyte Corporation $3,735.62 04/11/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675131
Principal investigator 1 Incyte Corporation $4,475.70 04/08/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675229
Principal investigator 1 Incyte Corporation $3,060.00 04/05/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675117
Principal investigator 1 Incyte Corporation $6,519.60 04/05/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675119
Principal investigator 1 Incyte Corporation $568.00 04/05/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675121
Principal investigator 1 Incyte Corporation $4,475.70 04/05/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675123
Principal investigator 1 Incyte Corporation $867.00 04/05/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675125
Principal investigator 1 Incyte Corporation $4,475.70 04/05/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675127
Principal investigator 1 Incyte Corporation $17,361.90 04/05/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675227
Principal investigator 1 Incyte Corporation $672.00 04/05/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675253
Principal investigator 1 Incyte Corporation $21,937.97 03/14/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675115
Principal investigator 1 Incyte Corporation $9,612.00 03/07/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675113
Principal investigator 1 Incyte Corporation $2,890.00 03/07/2024 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1134675223
Principal investigator 1 Sumitomo Pharma America, Inc. $3,067.00 02/15/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-Risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148446079
Principal investigator 1 Sumitomo Pharma America, Inc. $48,923.00 02/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-Risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148446077
Principal investigator 1 Sumitomo Pharma America, Inc. $24.30 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441758
Principal investigator 1 Sumitomo Pharma America, Inc. $24.30 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441762
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441766
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148441770
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442912
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442914
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442916
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442918
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148442920
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443777
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443779
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443781
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443783
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148443785
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148444307
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148444309
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445165
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445167
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445169
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 01/01/2024 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis No dispute reported 06/30/2026 1148445171